


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:


Listing of Claims:


1. (Currently Amended) [[An]] A use of derivatives of succinate esters of general formula (I) in the manufacture of the medicine for preventing or treating dementia:





(I)

wherein,

R₁ and R₄ are selected from -OCH₃, -OH, -O-Glu, , and




R₂ and R₃ are selected from H, -OH, -O-Glu, , and



R₅ is selected from non-branched or branched C₁₋₆ alkyls; and

[[The]] the configuration of chiral center at C-2 and C-3 are 2R3S, 2R3R, 2S3S and 2S3R respectively.


2. (Currently Amended) The use according to claim 1, characterized in that said compound of formula (I) is:




(I)

Wherein ~~wherein~~ wherein R₅ is selected from the group consisting of methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl; and R₁, R₂, R₃, and R₄ are the same as that in claim 1.


3. (Currently Amended) The use according to claim 2 characterized in that said compounds include:




;







;




;







;



1,4-bis(β-D-glucopyranosyloxybenzyl)-2-β-D-glucopyranosyl-2-isobutylmalate (dactylorhin
 A) (W8);





4. (Currently Amended) The use according to ~~claims~~ claim 1 [[1 ~ 3]], characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

5. (Original) The use according to claim 1, characterized in that said dementia includes Alzheimer' disease, vascular dementia, and learning and memory obstacle.

6. (Currently Amended) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to ~~claims~~ claim 1 [[1 ~ 4]] and a pharmaceutically acceptable carrier.

7. (Currently Amended) The pharmaceutical composition according to claim 6, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, ~~controled~~ controlled released formulation and various microparticle systems.

8. (Original) An use of extract of *Coeloglossum viride* (L.) Hartm. var. *bracteatum* (Willd.) Richter in the manufacture of the drugs for preventing or treating dementia.

9. (Original) The use according to claim 8, characterized in that said dementia includes Alzheimer' disease, vascular dementia and learning and memory obstacle.

10. (Original) A pharmaceutical composition, comprising an effective amount of extracts according to claim 8 and a pharmaceutically acceptable carrier.

11. (Original) The pharmaceutical composition according to claim 10, characterized in that said pharmaceutical composition may be in the form of tablets, capsules, pills, injectable solutions, sustained released formulation, controled released formulation and various microparticle systems.

12. (New) The use according to claim 2, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

13. (New) The use according to claim 3, characterized in that said compounds include stereo-isomers and pharmaceutical acceptable salts.

14. (New) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 2 and a pharmaceutically acceptable carrier.

15. (New) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 3 and a pharmaceutically acceptable carrier.

16. (New) A pharmaceutical composition, comprising an effective amount of any one of the compounds according to claim 4 and a pharmaceutically acceptable carrier.